Astra to Split Drug Production Along China-US Fault Lines (1)

AstraZeneca Plc is fleshing out plans for a manufacturing network that will independently supply drugs to major markets as the US pushes to reduce the pharma industry’s reliance on China.

The UK drugmaker will make the same medicine at different facilities to serve various markets separately, Chief Executive Officer Pascal Soriot said in an interview from the sidelines of the Bo’ao Forum for Asia.

“We’re organizing ourselves so we can supply the US and Europe independently,” he said Wednesday from the tropical island Hainan in southern China, where the event is held. “We also are building a presence here in ...